Literature DB >> 10915103

Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago.

L M Bahia-Oliveira1, J A Gomes, J R Cançado, T C Ferrari, E M Lemos, Z M Luz, M C Moreira, G Gazzinelli, R Correa-Oliveira.   

Abstract

We recently evaluated the in vitro proliferative response and interferon (IFN)-gamma production of peripheral blood mononuclear cells from a group of 25 people who were treated for Chagas' disease during the acute phase of Trypanosoma cruzi infection and followed up for a period of 14-30 years. On the basis of the parasitological and serological tests, the individuals were classified as cured (C), dissociated, or not cured (NC). Members of group C (the group without cardiac alterations) presented significantly stronger proliferative response against the parasite antigens, with secretion of high levels of IFN-gamma in comparison with the NC group, raising a question about the role of this cytokine in the curing of human T. cruzi infection. Severe cardiac alterations were observed only in 1 of 25 patients, which suggests that treatment benefited the patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915103     DOI: 10.1086/315743

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease.

Authors:  Walderez Ornelas Dutra; Cristiane Alves Silva Menezes; Fernanda Nobre Amaral Villani; Germano Carneiro da Costa; Alexandre Barcelos Morais da Silveira; Débora d'Avila Reis; Kenneth J Gollob
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

4.  Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children.

Authors:  María Cecilia Albareda; Gabriela Carina Olivera; Ana María De Rissio; Miriam Postan
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Use of the EIE-recombinant-Chagas-biomanguinhos kit to monitor cure of human Chagas' disease.

Authors:  Edimilson D Silva; Valéria R A Pereira; Juliana A S Gomes; Virgínia Maria B Lorena; Joaquim R Cançado; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response.

Authors:  J A S Gomes; L M G Bahia-Oliveira; M O C Rocha; O A Martins-Filho; G Gazzinelli; R Correa-Oliveira
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

9.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.

Authors:  Shilpi Khare; Xianzhong Liu; Monique Stinson; Ianne Rivera; Todd Groessl; Tove Tuntland; Vince Yeh; Ben Wen; Valentina Molteni; Richard Glynne; Frantisek Supek
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

10.  Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.